Source:http://linkedlifedata.com/resource/pubmed/id/11073351
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2001-2-5
|
pubmed:abstractText |
Dehydroepiandrosterone sulfate (DHEAS) was measured in random persons of three age cohorts (75, 80 and 85 years, N=271) at five-year intervals in order to find out predictors and significance of declining DHEAS in old age. The mean values decreased from 2.88 micromol/L to 2.39 micromol/L in men (p<0.001), and from 1.93 micromol/L to 1.73 micromol/L in women (p<0.05) at entry. Strong correlations were found between the baseline levels of DHEAS and those measured after five years both in men (r=0.727, p<0.001) and women (r=0.605, p<0.001), and the changes in DHEAS were associated with DHEAS levels at entry (r=-0.418, p<0.05). Baseline DHEAS was higher (2.47 micromol/L vs 2.05 micromol/L, p<0.05) and the decline more pronounced (-0.50 micromol/L vs 0.20 micromol/L, p<0.05) in the healthy subjects than in those suffering from diseases at entry, but the percentage five-year decline was similar (-6.5% and -5.2%) in both groups. The five-year decline in DHEAS was predicted neither by the baseline levels of risk indicators, e.g., serum lipids, body mass index, electrocardiographic, nor echocardiographic findings at entry. The age-and gender-adjusted baseline levels of DHEAS predicted neither mortality nor cognitive decline with 5- and 10-year follow-up periods. The 5-year decline in DHEAS was significant (p<0.05) in the subjects who died or developed cognitive decline during the subsequent 5-year follow-up. However, the changes did not differ significantly from those with favorable prognosis. The data indicate that the decline in DHEAS is primarily a gender-specific aging phenomenon, and only partly a consequence of actual diseases and frailty.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0394-9532
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
308-14
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11073351-Aged,
pubmed-meshheading:11073351-Aged, 80 and over,
pubmed-meshheading:11073351-Aging,
pubmed-meshheading:11073351-Cognition,
pubmed-meshheading:11073351-Cognition Disorders,
pubmed-meshheading:11073351-Cohort Studies,
pubmed-meshheading:11073351-Dehydroepiandrosterone Sulfate,
pubmed-meshheading:11073351-Female,
pubmed-meshheading:11073351-Humans,
pubmed-meshheading:11073351-Male,
pubmed-meshheading:11073351-Prognosis,
pubmed-meshheading:11073351-Survival Analysis,
pubmed-meshheading:11073351-Time Factors
|
pubmed:year |
2000
|
pubmed:articleTitle |
Predictors and clinical significance of declining plasma dehydroepiandrosterone sulfate in old age.
|
pubmed:affiliation |
Department of Medicine, Helsinki University Central Hospital, Finland.
|
pubmed:publicationType |
Journal Article
|